Cancer Immunotherapy: Basic Mechanisms Informing Clinical Applications & Combinations
Mar 15–18, 2026 | Fairmont Le Château Frontenac, Québec, QC, Canada
Scientific Organizers:
Jennifer Guerriero, Thomas Marron, Ira Mellman and Solange Peters
Mar 15–18, 2026 | Fairmont Le Château Frontenac, Québec, QC, Canada
Scientific Organizers:
Jennifer Guerriero, Thomas Marron, Ira Mellman and Solange Peters
Available Formats:
Supported by the Directors' Fund
In Person
On Demand
***Meeting program subject to change.
Available Formats: = In Person = On DemandSunday, March 15, 2026
Fundraising
Booking Function
Merchandise Options
Registration Options
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Monday, March 16, 2026
Breakfast
7:00–8:00 AM
Welcome and Keynote Address
8:00–9:00 AM
Elizabeth M. Jaffee, Johns Hopkins University
Cancer Immunotherapy - Where do we Stand Now?
Cancer Immunotherapy - Where do we Stand Now?
The Failures, Successes and Future of Cancer Immunotherapy
9:00–11:15 AM
Solange Peters, CHUV
Postmortem of Failed Immunotherapy Approaches
Postmortem of Failed Immunotherapy Approaches
Alexandra Snyder, Generate Biomedicines, Inc.
Talk Title to be Announced
Talk Title to be Announced
Ira Mellman, Medici Therapeutics
The Future of Cancer Immunotherapy
The Future of Cancer Immunotherapy
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
Poster Setup
11:15–1:00 PM
On Own for Lunch
11:15–5:00 PM
Poster Viewing
1:00–10:00 PM
Panel Discussion 1: Accelerating Development and Overcoming Regulatory Challenges of Drug Approvals
2:30–4:30 PM
Coffee Available
4:30–5:00 PM
Probing Omics and Big Data to Identify Novel Therapeutic Targets and Biomarkers
5:00–7:00 PM
Arielle Elkrief, Université de Montréal
The Gut Microbiome as a Therapeutic Target in Immuno-oncology
The Gut Microbiome as a Therapeutic Target in Immuno-oncology
Padmanee Sharma, University of Texas MD Anderson Cancer Center
From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy
From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy
Özlem Türeci, BioNTech
Vaccines
Vaccines
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Tuesday, March 17, 2026
Breakfast
7:00–8:00 AM
Advances and Challenges of Combination Immunotherapy of Cancer
8:00–11:00 AM
Sandra Demaria, Weill Cornell Medical College
Challenges and Opportunities to Improve Responses to Radiation and Immunotherapy Combinations
Challenges and Opportunities to Improve Responses to Radiation and Immunotherapy Combinations
Thomas Powles, Barts Cancer Institute
How to Optimally Combine Chemotherapies and Targeted Therapies with Immunotherapy
How to Optimally Combine Chemotherapies and Targeted Therapies with Immunotherapy
Thomas Marron, Icahn School of Medicine at Mount Sinai
Neoadjuvant Combination Immunotherapy Approaches: Improving Outcomes and Propelling the Science
Neoadjuvant Combination Immunotherapy Approaches: Improving Outcomes and Propelling the Science
James P. Allison, University of Texas MD Anderson Cancer Center
Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanistic Insights Provide New Therapeutic Opportunities
Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanistic Insights Provide New Therapeutic Opportunities
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Poster Setup
11:00–1:00 PM
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Panel Discussion 2: “Lessons Learned” from Combination Therapy: What can be Learned from the Failures to Improve Future Successes in Combination Treatment
1:30–3:15 PM
Career Roundtable
3:30–4:30 PM
Coffee Available
4:30–5:00 PM
Novel Approaches for Targeting Myeloid and Stromal Cells in the Tumor Microenvironment
5:00–7:00 PM
Shannon J Turley, Genentech, Inc.
Talk Title to be Announced
Talk Title to be Announced
Karin E. de Visser, Netherlands Cancer Institute
Crosstalk between Eosinophils and Adaptive Immune Cells: A New Avenue for Immune Checkpoint Blockade
Crosstalk between Eosinophils and Adaptive Immune Cells: A New Avenue for Immune Checkpoint Blockade
Jennifer Guerriero, Brigham and Women's Hospital
Harnessing Macrophages for Anti-Cancer Therapy
Harnessing Macrophages for Anti-Cancer Therapy
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Wednesday, March 18, 2026
Breakfast
7:00–8:00 AM
Novel Insights into Tumor Recognition by Lymphocytes
8:00–11:00 AM
Tullia C. Bruno, University of Pittsburgh
B Cells
B Cells
Miriam Merad, Mount Sinai School of Medicine
Novel Insights into the Organization of TLS
Novel Insights into the Organization of TLS
E. John Wherry, University of Pennsylvania
Novel T Cell Checkpoints
Novel T Cell Checkpoints
Carl H June, University of Pennsylvania
Cellular Therapies
Cellular Therapies
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
On Own for Lunch
11:00–5:00 PM
Workshop: Novel Platforms to Understand Mechanisms of Action and Resistance
2:30–4:30 PM
Coffee Available
4:30–5:00 PM
Cancer Immunotherapy: Overcoming Resistance
5:00–6:45 PM
Hélène Salmon, Institut Curie
Factors of TME Resistance
Factors of TME Resistance
Charles Swanton, Francis Crick Institute
Clonal Evolution and Immune Evasion
Clonal Evolution and Immune Evasion
Speaker to be Announced
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Social Hour with Lite Bites
7:00–8:00 PM
Cash Bar
8:00–11:00 PM
Entertainment
8:00–11:00 PM
Thursday, March 19, 2026
Departure
12:00–11:59 PM
Subscribe for Updates